Provided by Tiger Trade Technology Pte. Ltd.

ANTENGENE-B

3.930
+0.0401.03%
Volume:1.65M
Turnover:6.54M
Market Cap:2.66B
PE:-8.87
High:4.120
Open:4.050
Low:3.900
Close:3.890
52wk High:8.160
52wk Low:2.760
Shares:677.00M
HK Float Shares:677.00M
Volume Ratio:1.01
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.443
ROE:6.39%
ROA:7.21%
PB:2.50
PE(LYR):-8.87
PS:4.04

Loading ...

Antengene Receives Clinical Trial Approval in Australia for Phase I Attract Study of Atg-201 (Cd19 X Cd3 Tce) in B Cell-Related Autoimmune Diseases

THOMSON REUTERS
·
7 hours ago

Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy

Stock News
·
8 hours ago

Antengene Receives Australian HREC Green Light for Phase I “ATTRACT” Trial of Bispecific Antibody ATG-201

Bulletin Express
·
8 hours ago

Antengene Says Australia HREC Clears Phase 1 Attract Trial of ATG-201 in B-Cell Autoimmune Diseases

Reuters
·
8 hours ago

Antengene Corp - Receives Hrec Approval for Phase I Attract Study of Atg-201 in Australia

THOMSON REUTERS
·
8 hours ago

China's InnoCare Pharma H1 Revenue Surges, Partly on Orelabrutinib Growth

Reuters
·
Yesterday

Press Release: Antengene Announces 2026 Interim Results: Achieves First

Dow Jones
·
Yesterday

Antengene (SEHK:6996) Stock Drops As Profit Arrives And Valuation Looms

Simply Wall St.
·
Aug 23

Niki BioSolutions Weighs Financing Options as Going-Concern Warning Clouds Post-Merger Outlook

Reuters
·
Aug 22

China's Henlius H1 Revenue Jumps on Drug Sales, License Income

Reuters
·
Aug 21

Antengene-B Turns Profitable in First Half with Net Income of RMB216 Million

Stock News
·
Aug 21

Antengene: H1 2026 Revenue Jumps Nearly Tenfold to RMB 513.08 Million, Swings to RMB 216.35 Million Profit on Licensing Windfall

Bulletin Express
·
Aug 21

Biotech Firm Antengene's H1 Revenue Jumps on Licensing Deals

Reuters
·
Aug 21

Antengene FY26 H1 Returns to Profit at RMB 216.35 Million; Revenue More than Doubled to RMB 513.08 Million

Reuters
·
Aug 21

Antengene Corporation H1 Net Income Attributable RMB 216.3 Million

THOMSON REUTERS
·
Aug 21

Antengene Says Phase II Gastric Cancer Study Shows 46.7% ORR for ATG-022 at 1.8 Mg/kg Dose

Reuters
·
Aug 19

Antengene Schedules 21 Aug 2026 Board Meeting to Approve H1 2026 Interim Results

Bulletin Express
·
Aug 11

Antengene Sets Board Meeting to Review Interim Results

Reuters
·
Aug 11

Antengene Files Board, Board Committee Member List with Disclosure Roles

Reuters
·
Aug 03

Antengene's CFO Steps Down; Chief Business Officer Named

MT Newswires Live
·
Jul 31